Merck taps Abide for up to $430m diabetes deal
This article was originally published in Scrip
In its second deal around diabetes this week, Merck & Co has entered into a collaboration worth up to $430 million to use Abide Therapeutics' platform targeting a group of enzymes known as serine hydrolases to discover, develop and commercialize small-molecule therapies against three novel targets for metabolic diseases with a focus on type 2 diabetes.
You may also be interested in...
Private Company Edition: While venture capital invested in the industry dropped in 2019, the number of deals rose as investors funded more early-stage VC rounds. Money continues flowing to large deals as well, including $105m for ALX Oncology and $98m for CANbridge.
Public Company Edition: Five out of six drug developers and a CRO have seen their values spike immediately after going public this month. Also, Moderna floats a $500m offering, Revance proposes a $20m note sale, and Nestle invests another $200m in Aimmune.
Biohaven is still studying its glutamate modulator in three other indications, but its biggest near-term milestone will be approval of the oral CGRP inhibitor rimegepant for acute migraine.